Hemophilia A Treatment Market Size, Analytical Overview, Growth Factors, Demand and Trends Forecast to 2022
Hemophilia A patients have begun to shift from short acting to EHL factors and from on demand therapies to prophylactics. The increasing prevalent population of Hemophilia A and the rise in demand of the prophylactics treatments in developed markets will have a great impact on this market.
According to the US Centers for Disease Control and Prevention, hemophilia A occurs in 1 in 5,000 live male births. Hemophilia A is about four times as common as hemophilia B. The number of people with hemophilia in the United States is estimated to be about 20,000 individuals. Approximately 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment.
Get sample copy of this report @ https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment-market/request-for-sample
As of January 2018, there are over 450 reported Clinical Trials for Hemophilia A with 50+ trials currently actively ongoing. Out of all the trials, 120+ studies are funded by the pharmaceutical companies alone. The major players with drugs in Phase III are Alnylam Pharmaceuticals, Sanofi (Genzyme), BioMarin Pharmaceutical, Hoffmann-La Roche, Sinocelltech Ltd., Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Octapharma, LFB USA, Inc., Novo Nordisk A/S, Pfizer and others.
Polaris Market Research expects that with the expected launch of the promising treatments, the market is expected to expand in Hemophilia A segment. The United States dominates the Hemophilia A treatment market followed by Europe 5 and Japan. The prophylaxis segments are predicted to be the fastest growing segment whereas the on-demand therapy segment is expected to contribute close to ~50% to the market during the forecast period. With the increase in the R&D investments and rising drug innovations in this field, the market is expected to significantly expand in the next five years.
Browse for full research summary: https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment-market
RNA based therapeutics and curative gene therapies are rapidly progressing through clinical development and are seen as an attractive segment of this market.
Market Size & Forecast of Hemophilia A Treatment(2016-2022)
- Market Forecast by Disease Care
- Prophylaxis-Market Forecast (2016-2022)
- On-demand therapy-Market Forecast (2016-2022)
- Inhibitor therapy- Market Forecast (2016-2022)
- Market Forecast by G7 Countries (2016-2022)
- United States- Market Forecast (2016-2022)
- Germany- Market Forecast (2016-2022)
- France-Market Forecast (2016-2022)
- Italy- Market Forecast (2016-2022)
- Spain- Market Forecast (2016-2022)
- United Kingdom- Market Forecast (2016-2022)
- Japan- Market Forecast (2016-2022)
Avail discount on this report @ https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment-market/request-for-discount-pricing
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. We provide unmatched quality of offerings to our clients present globally. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world.
Contact us-
Mr. Likhil
Corporate Sales, USA
Polaris Market Research
Phone: 1-646-568-9980